Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells–a type of cancer immunotherapy–that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells–a type of cancer immunotherapy–that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.